Free shipping at $80
Nutrition
Chicken sounded perfectly normal last month. Now one look at it and absolutely not. Food aversions can make eating enough surprisingly difficult on a GLP-1. Here's what may be going on and how to work around it.
You bought the chicken.
You meal-prepped the chicken.
You seasoned the chicken.
And now apparently you and chicken are no longer speaking.
One of the stranger parts of life on a GLP-1 can be realizing that a food you used to genuinely enjoy suddenly sounds completely unappealing.
Sometimes it's meat.
Sometimes eggs.
Sometimes coffee.
Sometimes anything warm, rich or strongly scented.
And sometimes the answer to:
“What sounds good?”
is:
“Absolutely nothing. Thank you for asking.”
There is actually some science behind the fact that food can feel different during GLP-1 treatment.
Studies have documented changes in appetite, food intake, cravings and food preferences with medications including semaglutide and tirzepatide.
A major 2025 nutrition advisory from four professional organizations also notes clinical reports of food aversions, sometimes severe, particularly around treatment initiation and dose increases.
But there is an important distinction.
Researchers can measure changes in appetite and food preference.
That does not mean science can tell us exactly why your previously beloved rotisserie chicken has suddenly become your mortal enemy.
So let's separate what we know from what your refrigerator is currently doing to you.
The obvious effect is smaller appetite.
But researchers have also measured changes in the kinds of foods people want.
In a randomized semaglutide study in adults with obesity, participants ate substantially less during unrestricted meals after 12 weeks of treatment.
They also reported less hunger and fewer food cravings, and testing found a lower relative preference for high-fat foods.
That doesn't prove semaglutide creates “food aversions.”
But it does tell us something important:
the eating experience can change in more ways than simply feeling full sooner.
More recent research with tirzepatide has gone even further into what happens to food preferences.
In an 18-week randomized trial involving adults with obesity, researchers measured food preferences and cravings rather than simply asking whether people were hungry.
And the changes were not subtle.
Compared with placebo, tirzepatide reduced most of the food-preference measures researchers tested.
Cravings for sweets, carbohydrates and starches, and fast-food fats also fell.
Again:
this is not proof that tirzepatide causes your personal feud with scrambled eggs.
It is evidence that the medication can influence the drive toward certain foods.
Probably because several things can be happening at once.
GLP-1-based medications can reduce hunger.
They can increase fullness.
They can change food cravings and preferences.
They can also cause gastrointestinal symptoms such as nausea, particularly during treatment initiation or dose escalation.
Put those together and a food that once sounded completely normal may suddenly feel like far too much.
Especially if it is:
But we need to be careful here.
Research has documented changes in food preferences and clinical reports of food aversion.
It has NOT established one universal biological pathway explaining every specific aversion.
Your suddenly hostile relationship with chicken may involve appetite, nausea, learned association, smell, texture, fullness or several things at once.
Human eating behavior is annoyingly complicated.
It's Not Just “Less Hungry”
Research supports changes across several parts of eating behavior during GLP-1 treatment. It does not prove why one particular food suddenly becomes unappealing to one particular person.
This isn't just something appearing in Reddit threads.
A 2025 joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association and The Obesity Society specifically discusses changes in food preferences during GLP-1 therapy.
The authors note clinical reports of food aversions, sometimes severe, particularly when treatment begins and around dose increases.
That is important.
But it is also different from saying:
“Clinical trials prove 37% of people suddenly hate meat.”
We do not have a clean population-wide percentage for food aversion.
So if someone gives you one without showing you the study:
eyebrow up.
This Is Showing Up in Clinical Practice
Food aversions are now part of the nutrition conversation.
A 2025 joint advisory from four major professional organizations notes that some people report food aversions during GLP-1 treatment, sometimes severe, particularly around treatment initiation and dose increases.
The advisory describes clinical experience and the broader evidence on GLP-1 nutrition. It does not provide a population-wide incidence rate for food aversion. Source: 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society.
You are allowed to break up with chicken.
Chicken will recover.
The nutritional issue begins when your list of foods you can comfortably eat becomes so short that meeting your needs becomes difficult.
Reduced hunger and increased fullness can already make total food intake smaller.
Add nausea or several food aversions and suddenly the day's intake can become:
That is where food aversion stops being merely weird and becomes nutritionally relevant.
The goal is not to force yourself to eat a specific food because somebody on the internet declared it “perfect for GLP-1s.”
The goal is to find foods you tolerate that still help you get enough nutrition.
The Rule
Your nutrition doesn't have to look the same every week.
If chicken suddenly makes you want to leave the building, chicken does not need to be the hill you die on.
The goal is finding foods you can comfortably eat that still help you meet your nutritional needs.
Work with your appetite, not against it
If one protein source suddenly sounds terrible, you have not failed nutrition.
Try another.
Depending on what you tolerate, that might mean:
If eggs have committed an unforgivable crime this week, eggs can sit this one out.
Hot food usually smells stronger.
When nausea or smell sensitivity is part of the problem, cooler foods may be easier for some people to tolerate.
A cold yogurt bowl may sound manageable when the smell of something cooking absolutely does not.
This is not a biological law.
It is a practical experiment.
A smaller appetite does not require a ceremonial full-sized meal.
If a giant dinner looks overwhelming, think smaller.
A few bites now.
Something else later.
A small snack with useful nutrition.
Another opportunity in a few hours.
The 2025 joint nutrition advisory specifically recommends smaller, more frequent meals in the context of GLP-1-related nausea.
Your meal does not need to win Meal of the Year.
It needs to be edible.
Sometimes the problem is not “protein.”
It's that the thought of chewing a dense piece of meat for seven business days feels impossible.
Different textures can matter.
Soft.
Cold.
Crunchy.
Smooth.
Liquid.
Find the version your brain is currently willing to negotiate with.
The 2025 nutrition advisory describes a frustrating cycle:
nausea leads to not eating;
not eating can worsen nausea;
worsening nausea makes eating even less appealing.
If that sounds familiar, small amounts at regular intervals may be easier than waiting all day and then trying to negotiate with dinner.
Not a perfect meal plan.
Not a spreadsheet requiring conditional formatting.
A short list.
Foods that currently sound:
fine;
safe;
easy;
or at least not offensive.
When appetite is low, decision fatigue does not improve the situation.
Having five or six reliable options can be considerably more useful than staring into the refrigerator hoping inspiration arrives.
If you ate something and then spent the evening nauseous, it is not particularly surprising if your brain is less enthusiastic about seeing that food again.
Give it some space.
Try alternatives.
You can revisit it later if you want.
There is no nutritional medal for repeatedly confronting a chicken breast.
This is where we stop making chicken jokes for a minute.
If food aversion or nausea is making it genuinely difficult to eat enough, drink enough or maintain adequate nutrition, tell the clinician managing your medication.
Especially if you are also experiencing:
GLP-1 treatment is not supposed to become an endurance competition in how little you can eat.
Severe or persistent symptoms deserve medical attention.
Do not independently change a prescribed dose based on this article.
Maybe.
Food preferences are not necessarily fixed.
In the tirzepatide food-preference study, some effects became less pronounced over the 18-week treatment period, although differences from placebo remained.
That does NOT mean your personal food aversion will disappear on a specific timeline.
But it does mean we should not assume:
“I hate this food today”
equals:
“I will hate this food forever.”
So maybe don't hold a funeral for tacos just yet.
If food suddenly feels different on a GLP-1, you are not necessarily imagining it.
Research with semaglutide and tirzepatide has documented changes in appetite, food intake, cravings and food preferences.
A major nutrition advisory also notes that some people report food aversions, particularly around treatment initiation and dose increases.
What science cannot currently tell us is exactly why your specific formerly-beloved food has suddenly become unacceptable.
And that's okay.
You do not need to force one particular food.
Swap the food, not the nutritional goal.
Try smaller amounts.
Experiment with temperature and texture.
Keep a short list of foods that currently work.
And pay attention when “nothing sounds good” starts turning into “I'm barely eating or drinking.”
Because chicken can absolutely be dead to you for a while.
Your nutrition doesn't have to be.
Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017;19(9):1242–1251. doi:10.1111/dom.12932. PMID: 28266779.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5573908/
Kennedy SF, Knights A, Ravussin E, et al. Impact of tirzepatide treatment on participant-reported food craving and food preference: Secondary analyses of a phase 1 randomised controlled trial in people with obesity with dietary restriction. Diabetes, Obesity and Metabolism. 2025;27(11):6784–6789. doi:10.1111/dom.70063. PMID: 40874370.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12515769/
Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity Pillars. 2025;15:100181. doi:10.1016/j.obpill.2025.100181.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/
The Appendix provides general educational information and is not a substitute for individualized medical advice. Speak with your healthcare professional about questions specific to your health, medications or treatment.
TAKE next
When food sounds like a lot, keep it simple.
When your appetite is smaller or your usual protein foods suddenly aren't appealing, a shake can be an easier way to work protein into the day.
NOURISH
Plant-based protein with fava bean protein and YESTEIN™, plus MCT oil powder and apple pectin.*
